Poor
Partially Aligned
Patient Risk:
Moderate
Summary
Several statements match high-level label content (fibromyalgia indication; milnacipran inhibits norepinephrine/serotonin reuptake). However, multiple claims are not supported or are too specific/incorrect versus the provided label excerpts (e.g., 'increases levels' framing; pain/mood roles; specific symptom amplification 'turn down' wording; and multiple 'common side effects' not present in the provided label).
Category Scores
Accurate Statements
Savella (milnacipran) is used to treat fibromyalgia.
INDICATIONS AND USAGE: 'SAVELLA is indicated for the management of fibromyalgia.'
Savella increases the levels of serotonin in the brain.
12.1 Mechanism of Action: 'milnacipran is a potent inhibitor of neuronal norepinephrine and serotonin reuptake.' (Supports reuptake inhibition; label excerpt does not explicitly state 'increases levels'.)
Savella increases the levels of norepinephrine in the brain.
12.1 Mechanism of Action: 'Milnacipran is a potent inhibitor of neuronal norepinephrine and serotonin reuptake' and 'milnacipran inhibits norepinephrine uptake...' (Supports norepinephrine reuptake inhibition; label excerpt does not explicitly state 'increases levels').
Unsupported Statements
Serotonin and norepinephrine play a role in regulating pain perception.
Not supported by the provided label excerpts (12.1 states the exact mechanism is unknown and describes reuptake inhibition; no specific claim about pain perception role is included in the supplied text).
Serotonin and norepinephrine play a role in regulating mood.
Not supported by the provided label excerpts (12.1 mentions hypothesized associations with effects seen with other psychotropic drugs, but the specific mood-regulation claim is not stated in the provided text).
Fibromyalgia is characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory, and mood issues.
Not supported by the provided label excerpts.
Savella alleviates fibromyalgia symptoms by modulating pain pathways.
Contradicted by label wording in provided excerpt: 'The exact mechanism ... are unknown.' Provided text does not state 'modulating pain pathways.'
By increasing serotonin and norepinephrine, Savella may help turn down amplification of pain signals in the brain and spinal cord in people with fibromyalgia.
Not supported by the provided label excerpts; also the label excerpt states exact mechanism is unknown and does not describe 'amplification' or 'turn down' pain signals.
Common side effects of Savella include nausea.
No adverse reaction list (including nausea) is provided in the supplied label excerpts.
Common side effects of Savella include headache.
No adverse reaction list (including headache) is provided in the supplied label excerpts.
Common side effects of Savella include constipation.
No adverse reaction list (including constipation) is provided in the supplied label excerpts.
Common side effects of Savella include diarrhea.
No adverse reaction list (including diarrhea) is provided in the supplied label excerpts.
Common side effects of Savella include vomiting.
No adverse reaction list (including vomiting) is provided in the supplied label excerpts.
Common side effects of Savella include dizziness.
No adverse reaction list (including dizziness) is provided in the supplied label excerpts.
Common side effects of Savella include insomnia.
No adverse reaction list (including insomnia) is provided in the supplied label excerpts.
Common side effects of Savella include increased blood pressure.
The provided excerpt supports elevated blood pressure as a warning/precaution (5.3) and provides blood pressure monitoring language, but the provided text does not label it as a 'common side effect.'
Savella can cause side effects.
Vague generality; not stated as a specific claim in the provided excerpts (could be inferred, but the report policy requires support by supplied label text).
Savella is one of several medications approved for fibromyalgia treatment.
Not supported by the provided label excerpts.
Pregabalin is commonly prescribed for fibromyalgia.
Not supported by the provided label excerpts.
Duloxetine is commonly prescribed for fibromyalgia.
Not supported by the provided label excerpts.
Contradictions
Low
AI Statement
Savella alleviates fibromyalgia symptoms by modulating pain pathways.
Label Reference
12.1 Mechanism of Action: 'The exact mechanism of the central pain inhibitory action of milnacipran and its ability to improve the symptoms of fibromyalgia in humans are unknown.'
Important Omissions
Key prescribing-information safety content relevant to the provided excerpts (e.g., elevated blood pressure: measurement prior to initiation and periodic monitoring; caution with combinations that increase blood pressure/heart rate; use with caution in significant hypertension/cardiac disease; and catecholamine-related warning about concomitant epinephrine/norepinephrine and paroxysmal hypertension/possible arrhythmia).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported/overly specific efficacy mechanism claims and multiple 'common side effect' assertions are not supported by the supplied label excerpts. Additionally, elevated blood pressure exists in the label excerpt as a safety concern requiring monitoring, but the AI response does not capture the label’s monitoring/caution language.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are not supported by the provided prescribing-information excerpts, especially detailed 'common side effects' and specific mechanistic/effects-on-pain-signal wording.
Suggested Improvement
Limit mechanistic statements to what the label excerpt explicitly provides (inhibition of neuronal norepinephrine and serotonin reuptake; exact mechanism of symptom improvement unknown). Do not list side effects as 'common' unless supported by the adverse reactions section text provided. Include label-specific monitoring/caution for elevated blood pressure if making safety-related claims.